p ROTO-ONCOGENES are usually involved in the normal growth, maturation, and differentiation of cells, including those of the central nervous system (CNS).I However, the oncogenic potential of these genes may be changed by genetic alterations such as gene amplification (increased copies of the gene per cell), chromosomal translocation (relocation within the genome which results in increased expression of a single gene), and point mutation (producing a gene product with increased oncogenic potency). Among CNS tumors, the N-myc gene amplification is frequently found in neuroblastomas 6 and is also seen less frequently in other neuroectodermal tumors such as retinoblastomas,18 small-cell lung cancers, 23 and malignant astrocytomas. 12 In addition, the epidermal growth factor (EGF) receptor gene and c-myc amplification are found in glioblastomas multiforrne. 2~ On the other hand, karyotypic analyses of tumors of the CNS have shown chromosome 22 to be abnormal. Studies have demonstrated the deletion of this chromosome in gliomas and meningiomas, 32 chromosomal translocation t (14;22) in leukocytes of patients with familial meningioma, 4 and chromosomal translocation t(1 1;22) in peripheral neuroepitheliomas (peripheral neuroblastomas). 31 In recent years, it has become clear that the sis oncogene is mapped to chromosome 229 and that it encodes the B chain of platelet-derived growth factor (PDGF). 3~ Cultured human glioblastoma cells express the sis oncogene and secrete a PDGF-Iike substance. 25 Stimulation by PDGF produces rapid transient expression of the myc and fos genes and their protein products in quiescent cells.15 '16'22 The gene products of myc and fos are nuclear proteins and may play a role in deoxyribonucleic acid (DNA) synthesis. ~5.t9
This study of 10 primary human brain tumors of neuroectodermal origin examined the messenger ribonucleic acid (mRNA) accumulation and the possible amplification of four proto-oncogenes (N-myc, c-myc, v-sis, and v-fos), which seem to be highly correlated with tumors of the CNS.
Materials and Methods
Brain-tumor specimens were obtained at the time of operation and immediately stored in liquid nitrogen to ensure preservation of the RNA and DNA. The following tumors were collected: four glioblastomas multiforme, one mixed glioma (astrocytoma grade 1 and ependymoma), one astrocytoma grade II, one cystic Proto-oncogene analyses in brain tumors cerebellar astrocytoma, one ependymoma, one ganglioglioma, and one medulloblastoma. The brain of a normal adult baboon was used for control studies. The relevant information associated with these tumors is listed in Table 1 . The tumors in Cases 2 (glioblastoma) and 10 (medulloblastoma) were recurrent neoplasms and the patients died 3 and 2 months, respectively, after the second operation.
Total RNA was isolated by the guanidinium/cesium chloride method. 8'~3 Polyadenylated (poly(A) § RNA was collected using oligothymidylic acid-cellulose column chromatographyfl The quantity of poly(A) + RNA extracted from the tumor specimens was estimated by ethidium bromide/agarose plate assay. 7 The samples were then denatured by immersion in 6.4% formaldehyde and 48% formamide followed by heating at 65~ for 15 minutes. Denatured poly(A) § RNA's (3 ~zg) from the tumors and from the normal baboon brain were separated by electrophoresis using 1% agarose gels containing 2.2 M formaldehyde, and were transferred to a BA-85 nitrocellulose filter.* The nitrocellulose filter was air-dried and baked at 800C in a vacuum for 3 hours. The filter was prehybridized for 1 hour at 42"C in a solution containing 50% formamide, 2 x SET (3 M NaC1, 20 mM ethylenediaminetetra-acetic acid, and 0.4 M Tris-C1 (pH 7.8)), 2 • Denhardt solution (0.02% Ficoll solution, 0.02% polyvinylpyrrolidone, and 0.02% bovine serum albumin), 0.1% sodium dodecyl sulfate (SDS), 0.1% NaPPi, 100 ug/ml salmon sperm DNA (sonicated, sheared, and denatured), and 10% dextran sulfate. Oncogenes (N-myc, c-myc, v-sis, and v-fos) and B-actin inserts were removed from the plasmid using appropriate enzymes, labeled with a-phosphorus-32 deoxycytidine triphosphate (3000 Ci/mmol) by the oligolabeling procedure described elsewhere.~~ The filters were first incubated at 65~ for 5 minutes and then hybridized at 42"C for 16 hours using 5 x 10 ~ cpm of the labeled oncogene or 5 x l05 cpm of the B-actin DNA/ml of hybridization solution.
After hybridization was complete, the filter was washed three times for 10 minutes each in 2 • standard saline citrate (SSC), 0.1% SDS, and 0.1% NaPPi at room temperature, then in 0.2 x SSC and 0.1% SDS at 50"C for 1 hour. The filter was air-dried and exposed at -70"C for 24 to 48 hours to Kodak XAR-5 x-ray film with a Cronex intensifying screen, t High-molecular-weight DNA's from tumors were prepared by the technique described by Blin and Stafford? A 10-t~g aliquot of DNA from each sample was digested with the restriction endonucleases EcoRI, Hind III, or BamHI, fractionated by electrophoresis in a 0.6% agarose gel, and transferred to nitrocellulose filters. Hybridization of the filters and exposure to x-ray film * Nitrocellulose filter made by Schleicher & Schuell, Inc., Keene, New Hampshire.
t XAR-5 x-ray film manufactured by Eastman Kodak, Rochester, New York; Cronex intensifying screen manufactured by Du Pont, Wilmington, Delaware. were carried out under the same conditions as for RNA blot filter.
The N-myc probe was a 1.0-kilobase pair (kbp) EcoRI-BamHI fragment obtained from the clone pNB-1. The human c-myc probe was a 1.4-kbp ClaI-EcoRI fragment containing the third exon from pHSR I. Both v-sis and v-fos were 1.1-kbp PstI fragments. The chicken B-actin complementary DNA probe was a 2.0-kbp Hind III fragment. The relative amount of mRNA and the potential DNA amplification of the proto-oncogenes and B-actin were estimated by densitometric analysis of the autoradiograms using a scanning densitometer.~
Results
Results of the RNA blot analysis using N-myc, cmyc, v-sis, v-fos, and chicken B-actin probes for samples obtained from the 10 brain tumors and normal baboon brain are shown in Fig. 1 . The N-myc DNA hybridized strongly to the RNA from the recurrent glioblastoma in Case 2 (Fig. 1A) . The c-myc probe showed greater hybridization to the RNA from the recurrent medulloblastoma in Case 10 than from the other tumors (Fig.  1B) . The v-sis probe demonstrated an accumulation of homologous RNA in samples from the recurrent glioblastoma in Case 2 and from the ganglioglioma in Case 9 (Fig. 1C) . The v-fos DNA also showed a substantial accumulation of homologous RNA in samples from benign gliomas (Fig. 1D) .
The relative amount of poly(A) + RNA hybridizing to the four oncogene probes in Fig. 1 was determined by scanning densitometry. The intensity of the bands z~ Scanning densitometer manufactured by Scientific Instruments, San Francisco, California. Lower Lanes: After autoradiography, the radioactivity was removed from the nitrocellulose filter by boiling.
To control for the total m R N A of each sample, the same filters were then hybridized to the chicken B-actin complementary D N A probe, a 2.0-kbp Hind III fragment. (Fig. 2) . The intensity of the bands corresponding to specific mRNA's in given samples was normalized to B-actin. The values are expressed as a percentage of the signal intensity generated from tumors with the greatest accumulation of RNA (Case 2 for N-myc and v-sis, Case 10 for c-myc, and Case 8 for v-fos), which was arbitrarily set at 100%. Each value was rounded offto the nearest multiple of five. A value of< 1 means that the accumulation level of the mRNA in that tissue was detectable, although clearly below the 1% level, and too low to obtain a signal. (This definition is based on the system of Nisen, et aL 24) ND = not determined. FZG. 2. DNA blot analyses of the Nomyc (A), c-myc (B), v-sis (C), and v-fos (D) genes in brain tumors. Ten/~g of DNA from each sample was digested with EcoRI, Hind III, or BamHI, fractionated by agarose gel electrophoresis, transferred to nitrocellulose filters, and hybridized to each of the probes. The first lane in each illustration contains normal human leukocyte DNA as a measure of the single copy intensity (control). The extent of amplification was determined by densitometric analysis. The recurrent glioblastoma from Case 2 exhibited an 80-fold amplification of N-myc and one additional band (A). In addition, this tumor had a threeto fourfold amplification of v-sis (C). In contrast, the other oncogenes were not amplified even though c-myc RNA was highly accumulated in Case 10 (recurrent medulloblastoma) (B). These data are summarized in Table 2 .
TABLE 2

Accumulation of gene amplification of N-myc, c-myc, v-sis, and v-fos in primary human brain tumors of neuroectodermal origin*
Discussion
In a previous report on neuroblastoma cell lines, Nm y c gene amplification was associated with enhanced expression o f this gene. 21 Similarly, in this study, the abundant a c c u m u l a t i o n o f m R N A hybridizing to Nm y c and v-sis from the recurrent glioblastoma is probably due to gene amplification ( N -m y c 80 copies; v-sis three to four copies). T o date, there is only o n e report demonstrating the simultaneous amplifications o f t w o oncogenes in the same t u m o r . 28 In that t u m o r (a h u m a n lung giant-cell c a r c i n o m a maintained in n u d e mice) both K-ras a n d c -m y c were amplified, although n o evidence was presented that these amplifications had occurred in the original tumor tissue of the patient. The authors proposed that the amplifications probably occurred in the original tumor because multiple oncogenes were needed for malignant transformation. 17 However, in the case of both genes, it was unclear whether these proto-oncogenes participated in malignant transformation or whether the amplifications were the result of tumorigenesis. Gene amplification is frequently found in cultured cells which are resistant to a chemotherapeutic agent such as methotrexate. 27 These cells can produce large quantities of dihydrofolate reductase (the target of methotrexate), as a result of gene amplification. The amplification of the N-myc gene and elevated N-myc mRNA level in neuroblastomas appears to correlate with the clinical stage of the tumor and with the poor prognosis of the patients. 5'~4 Therefore, it is tempting to speculate that the N-myc protein is one of the essential products necessary for the aberrant behavior of these cells. Except for its ability to bind to DNA, the precise function of this protein is still unclear. 26 An interesting question is why other glioblastomas have relatively low accumulations of mRNA homologous to N-myc and sis and no amplification of either the N-myc or the sis gene. Two possibilities come to mind. First, even though the histological diagnosis is the same, the etiologies at the molecular level are quite different. The second possibility is that there was a sampling error associated with taking small samples of a large tumor. The finding that the recurrent medulloblastoma accumulated large quantities of mRNA coding for c-myc, but did not appear to have undergone any gene amplification, is also interesting. Since the karyotype of this tumor was not determined, the translocation of this gene can not be ruled out as a cause for the increased accumulation of mRNA coding for c-myc.
The levels of glioma mRNA homologous to N-myc, c-myc, and fos seem to be inversely correlated with each other's relative accumulation. A similar observation was reported concerning N-myc and c-myc accumulation in Wilm's tumor by Nisen, et al. 24 They suggested that the elevated N-myc expression might regulate downward c-myc expression in Wilm's tumor. However, the mechanism for the proposed cross-regulation is still totally unknown. In benign gliomas, the fos gene appears to be expressed ubiquitously compared with Nmyc and c-myc. The function of the fos gene is poorly understood. However, it has been proposed that this gene enhances metastatic ability 33 and that it can prevent a cell from entering into a quiescent state (Go)? 5 The presence of gene amplification and increased accumulations of mRNA coding for these proto-oncogenes (N-myc, c-myc, sis, and fos) may play a role in tumorigenesis and/or the aggressiveness of these malignant brain tumors of neuroectodermal origin, and they may be good molecular indicators of the extremely malignant state of these tumors. However, additional information is needed concerning proto-oncogene ex-pression and amplification in many more tumors before we can state with assurance that the prognosis of patients with malignant brain tumors is correlated with heightened accumulation of the mRNA coding for the proto-oncogenes and their gene amplification.
